Energy and Commerce Subcommittee Passes Mental Health and Substance Use Disorder Bill, Other Health Legislation

May 17, 2022

On Wednesday, the House Energy and Commerce Subcommittee on Health advanced legislation to reauthorize the Food and Drug Administration’s (FDA) medical product user fee programs, several mental health and substance use disorder programs, and establish an Advanced Research Projects Agency for Health.

The Food and Drug Amendments of 2022 (H.R.7667) reauthorize the FDA user fee programs and include several provisions to support patient access to drugs and devices and spur innovation. Subcommittee members highlighted policy issues with bipartisan consensus, including increasing diversity in clinical trials, bolstering the domestic medical supply chain, and improving cybersecurity for medical devices.

The Subcommittee also passed the Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666), which reauthorizes more than 30 programs that address  mental health and substance use disorder within the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration.

The full Energy and Commerce Committee is set to hold a markup as soon as next week. GNYHA will continue to monitor Congressional health committee discussions of policies that impact our members, including mental health legislation and regulation of laboratory developed tests.